204 related articles for article (PubMed ID: 33029680)
1. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.
Vijayvergia N; Dasari A
Curr Treat Options Oncol; 2020 Oct; 21(12):96. PubMed ID: 33029680
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in Tandem With 177 Lu-DOTATATE Therapy in Advanced Pancreatic Neuroendocrine Tumor : A New Treatment Approach.
Aggarwal P; Gunasekaran V; Sood A; Gupta K; Das CK; Mittal BR
Clin Nucl Med; 2024 Feb; 49(2):e85-e86. PubMed ID: 38109041
[TBL] [Abstract][Full Text] [Related]
3. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
Megdanova-Chipeva VG; Lamarca A; Backen A; McNamara MG; Barriuso J; Sergieva S; Gocheva L; Mansoor W; Manoharan P; Valle JW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708210
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison.
Kasajima A; Klöppel G
Endocr Relat Cancer; 2020 Nov; 27(11):R417-R432. PubMed ID: 33032264
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms.
Al-Toubah T; Cives M; Strosberg J
Transl Gastroenterol Hepatol; 2020; 5():54. PubMed ID: 33073049
[TBL] [Abstract][Full Text] [Related]
7. Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging.
Refardt J; Zandee WT; Brabander T; Feelders RA; Franssen GJH; Hofland LJ; Christ E; de Herder WW; Hofland J
Endocr Relat Cancer; 2020 Nov; 27(11):615-624. PubMed ID: 33032265
[TBL] [Abstract][Full Text] [Related]
8. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma.
Gao HL; Wang WQ; Yu XJ; Liu L
Exp Hematol Oncol; 2020; 9():28. PubMed ID: 33101770
[TBL] [Abstract][Full Text] [Related]
9. Neurotensin receptor 1 signaling promotes pancreatic cancer progression.
Takahashi K; Ehata S; Miyauchi K; Morishita Y; Miyazawa K; Miyazono K
Mol Oncol; 2021 Jan; 15(1):151-166. PubMed ID: 33034134
[TBL] [Abstract][Full Text] [Related]
10. Going Above and Beyond the Pancreatic Neuroendocrine Tumor Classification.
Gaujoux S; Menegaux F
JCO Oncol Pract; 2020 Nov; 16(11):731-732. PubMed ID: 33085932
[No Abstract] [Full Text] [Related]
11. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells.
Valle S; Alcalá S; Martin-Hijano L; Cabezas-Sáinz P; Navarro D; Muñoz ER; Yuste L; Tiwary K; Walter K; Ruiz-Cañas L; Alonso-Nocelo M; Rubiolo JA; González-Arnay E; Heeschen C; Garcia-Bermejo L; Hermann PC; Sánchez L; Sancho P; Fernández-Moreno MÁ; Sainz B
Nat Commun; 2020 Oct; 11(1):5265. PubMed ID: 33067432
[TBL] [Abstract][Full Text] [Related]
12. Divergent expression of DCLK1 in gastrointestinal neuroendocrine tumors and primary hepatic, gallbladder, and pancreatic neuroendocrine tumors.
Fan M; Yan H; Gou M; Qian N; Dai G
Int J Clin Exp Pathol; 2020; 13(9):2249-2258. PubMed ID: 33042329
[TBL] [Abstract][Full Text] [Related]
13. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors.
De Rycke O; Védie AL; Guarneri G; Nin F; De Flori C; Hentic O; Idri S; Sauvanet A; Rebours V; Cros J; Couvelard A; Ruszniewski P; de Mestier L
Pancreatology; 2020 Dec; 20(8):1718-1722. PubMed ID: 33032924
[TBL] [Abstract][Full Text] [Related]
14. Classification of neuroendocrine neoplasms: lights and shadows.
La Rosa S; Uccella S
Rev Endocr Metab Disord; 2021 Sep; 22(3):527-538. PubMed ID: 33169199
[TBL] [Abstract][Full Text] [Related]
15. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T
Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G; Wang Y; Zhang H; She X; Yang J
Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.
Ito T; Jensen RT
Expert Opin Pharmacother; 2021 Apr; 22(6):685-693. PubMed ID: 33131345
[No Abstract] [Full Text] [Related]
18. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
[TBL] [Abstract][Full Text] [Related]
19. High-dose Somatostatin Analogues for Progressive Neuroendocrine Tumours.
Sharp AJ; Hayes AR; Grossman A
Eur Endocrinol; 2020 Oct; 16(2):93-95. PubMed ID: 33117438
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
